Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02266875 · ClinicalTrials.gov registry record · Phase 4

Nebulized Hypertonic Saline for Inpatient Use in COPD

A Phase 4 study of Chronic Obstructive Pulmonary Disease, sponsored by OhioHealth.

Completed
Registry status
Phase 4
Development phase
70
Enrollment target
1
Study location

NCT02266875 is a Phase 4 study of Chronic Obstructive Pulmonary Disease that has completed, run by OhioHealth. The registered enrollment target is 70 participants, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02266875, a Phase 4 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by OhioHealth.

COMPLETED
Registry status
Phase 4
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

A comparison of albuterol treatments using hypertonic saline (3%) versus standard saline (0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale scores after 4 treatments within 24 hours.

Interventions

  • DRUG hypertonic saline
  • DRUG standard saline

Study Locations (1)

Ohio

  • Doctors Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2014-10
Est. Completion 2017-01-30
Phase Phase 4

Sponsor

OhioHealth

20 total trials

What the Registry Record Tells You About NCT02266875

The ClinicalTrials.gov registry entry for NCT02266875 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (96% lower). The listed sponsor is OhioHealth, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which hypertonic saline is the first listed.

NCT02266875 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT02266875 about?

NCT02266875 is a clinical study titled "Nebulized Hypertonic Saline for Inpatient Use in COPD". A comparison of albuterol treatments using hypertonic saline (3%) versus standard saline (0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale scores after 4 treatments within 24 hours.

What is the current status of trial NCT02266875?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2014-10. Estimated completion is 2017-01-30.

What conditions does trial NCT02266875 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.

What interventions are being tested in trial NCT02266875?

The interventions under investigation include: hypertonic saline (DRUG), standard saline (DRUG).

Who is sponsoring clinical trial NCT02266875?

This trial is sponsored by OhioHealth, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02266875 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Obstructive Pulmonary Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.